<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">It is a glucocorticoid that has been used for several years in the treatment of various inflammatory and autoimmune diseases. Preliminary results from the RECOVERY trial have shown that Dexamethasone reduces mortality by one-third in mechanically ventilated patients hospitalized with severe COVID-19, and by one-fifth in patients requiring oxygen without mechanical ventilation 
 <xref rid="b0375" ref-type="bibr">[75]</xref>. The drug did not improve survival in patients not requiring respiratory support. Dexamethasone has been approved for use as a COVID-19 treatment in the UK 
 <xref rid="b0380" ref-type="bibr">[76]</xref>. As is the case with other corticosteroids, Dexamethasone suppresses the immune system and could thus potentially exacerbate viral infections. However, its immunosuppressant effects might benefit COVID-19 patients who experience CRS.
</p>
